Advertisement

Locally advanced rectal cancer: qualitative and quantitative evaluation of diffusion-weighted magnetic resonance imaging in restaging after neoadjuvant chemo-radiotherapy

  • Maria NapoletanoEmail author
  • Daniele Mazzucca
  • Enrico Prosperi
  • Maria Cristina Aisa
  • Marco Lupattelli
  • Cynthia Aristei
  • Michele Scialpi
Special Section: Rectal Cancer
  • 72 Downloads

Abstract

Purpose

To determine the added value of qualitative and quantitative evaluation of diffusion-weighted magnetic resonance imaging (DWI) in locally advanced rectal cancer (LARC) restaging after neoadjuvant chemo-radiotherapy (CRT).

Materials and Methods

A retrospective study was performed of 21 patients with LARC treated with CRT. All patients were evaluated with 1.5 T conventional magnetic resonance imaging (MRI) and DWI (0–1000 s/mm²) before starting therapy and after neoadjuvant CRT. All included patients underwent surgery after CRT: the histopathological evaluation of surgical specimens represented the reference standard for local staging after neoadjuvant therapy. The qualitative analysis was carried out by two operators in consensus, who reviewed the conventional MR image set [T1-weighted and T2-weighted morphological sequences + dynamic contrast-enhanced sequences (DCE)] and the combined set of conventional and DW images. For the quantitative analysis, the apparent diffusion coefficient (ADC) values were measured at each examination. For each lesion, the mean ADC value (ADCpre and ADCpost) and the ΔADC (ADCpost – ADCpre) were calculated, and values of the three groups of response [complete response (pCR), partial response (pPR), stable disease (pSD)] were compared.

Results

In LARC restaging, conventional MRI showed a sensitivity of 80% and a specificity of 50%, with a total diagnostic capacity of 71.40%, while by adding DWI sensitivity increased to 100%, specificity to 67%, and total diagnostic capacity to 90.40%. ΔADC correlates with treatment response and a cutoff of 1.35 × 10−3 mm²/s predicts the pCR with a sensitivity of 93.3% and a specificity of 83.3%.

Conclusions

Adding DWI to conventional sequences may improve MRI capability to evaluate tumor response to CRT. The quantitative DWI assessment is promising, but larger studies are required.

Keywords

LARC DWI Chemo-radiotherapy 

Notes

References

  1. 1.
    Lezoche G, Baldarelli M, Guerrieri M, et al., A prospective randomized study with a 5-year minimum follow-up evaluation of transanal endoscopic microsurgery versus laparoscopic total mesorectal excision after neoadjuvant therapy, Surg Endosc, 2008;22:352-358.CrossRefGoogle Scholar
  2. 2.
    Lezoche E, Baldarelli M, Lezoche G, et al., Randomized clinical trial of endoluminal locoregional resection versus laparoscopic total mesorectal excision for T2 rectal cancer after neoadjuvant therapy, Br J Surg, 2012;99:1211-1218.CrossRefGoogle Scholar
  3. 3.
    Habr-Gama A, Perez MO, Nadalin W, et al., Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results, Ann Surg, 2004;240:711-717.Google Scholar
  4. 4.
    Marijnen CA, Kapiteijn E, van de Velde CJ, et al., Acute side effects and complications after short-term preoperative radiotherapy combined with total mesorectal excision in primary rectal cancer: report of a multicenter randomized trial, J Clin Oncol, 2002;20:817-825.CrossRefGoogle Scholar
  5. 5.
    Sartori CA, Sartori A, Vigna S, Occhipinti R, Baiocchi GL, Urinary and sexual disorders after laparoscopic TME for rectal cancer in males, J Gastrointest Surg, 2011;15:637-643.CrossRefGoogle Scholar
  6. 6.
    Maas M, Nelemans PJ, Valentini V, et al., Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data, Lancet Oncol, 2010;11:835-844.CrossRefGoogle Scholar
  7. 7.
    Perez RO, Habr-Gama A, Pereira GV, et al., Role of biopsies in patients with residual rectal cancer following neoadjuvant chemoradiation after downsizing: can they rule out persisting cancer?, Colorectal Dis, 2012;14:714-720.CrossRefGoogle Scholar
  8. 8.
    Hanly AM, Ryan EM, Rogers AC, et al., Multicenter Evaluation of Rectal cancer ReImaging pOst Neoadjuvant (MERRION) Therapy, Ann Surg, 2014;259:723-727.CrossRefGoogle Scholar
  9. 9.
    Huh JW, Park YA, Jung EJ, Lee KY, Sohn SK, Accuracy of endorectal ultrasonography and computed tomography for restaging rectal cancer after preoperative chemoradiation, J Am Coll Surg, 2008;207:7-12.CrossRefGoogle Scholar
  10. 10.
    Curvo-Semedo L, Lambregts DM, Maas M, et al., Diffusion-weighted MRI in rectal cancer: apparent diffusion coefficient as a potential noninvasive marker of tumor aggressiveness, J Magn Reson Imaging, 2012;35:1365-1371.CrossRefGoogle Scholar
  11. 11.
    Kim SH, Lee JM, Hong SH, et al., Locally advanced rectal cancer: added value of diffusion-weighted MR imaging in the evaluation of tumor response to neoadjuvant chemo- and radiation therapy, Radiology, 2009;253:116-125.CrossRefGoogle Scholar
  12. 12.
    Marouf RA, Tadros MY, Ahmed TY, Value of diffusion-weighted MR imaging in assessing response of neoadjuvant chemo and radiation therapy in locally advanced rectal cancer, Egyptian Journal of Radiology and Nuclear Medicine, 2015;46:553-561.CrossRefGoogle Scholar
  13. 13.
    Foti PV, Privitera G, Piana S, et al., Locally advanced rectal cancer: Qualitative and quantitative evaluation of diffusion-weighted MR imaging in the response assessment after neoadjuvant chemo-radiotherapy, Eur J Radiol Open, 2016;3:145-152.CrossRefGoogle Scholar
  14. 14.
    Bayram I, Bakir B, Kartal MGD, et al., The role of MRI with diffusion-weighted imaging in restaging rectal cancers after neoadjuvant chemoradiotherapy, S Afr J Rad, 2016;20(1):a967.CrossRefGoogle Scholar
  15. 15.
    The American Joint Commettee on Cancer, AJCC Cancer Staging Manual 8th edition, 2017.Google Scholar
  16. 16.
    Szafer A, Zhong J, Anderson AW, Gore JC, Diffusion-weighted imaging in tissues: theoretical models, NMR Biomed, 1995;8:289-96.CrossRefGoogle Scholar
  17. 17.
    Bassaneze T, Gonçalves JE, Faria JF, Palma RT, Waisberg J, Quantitative aspects of diffusion-weighted magnetic resonance imaging in rectal cancer response to neoadjuvant therapy, Radiol Oncol, 2017;51(3):270-276.CrossRefGoogle Scholar
  18. 18.
    Jang KM, Kim SH, Choi D, et al., Pathological correlation with diffusion restriction on diffusion-weighted imaging in patients with pathological complete response after neoadjuvant chemoradiation therapy for locally advanced rectal cancer: preliminary results, Br J Radiol, 2012;85:e566-e572.CrossRefGoogle Scholar
  19. 19.
    Pierredon-Foulongne MA, Nougaret S, Bibeau F, et al., Utility of reassessment after neoadjuvant therapy and difficulties in interpretation, Diagn Interv Imaging, 2014;95:495-503.CrossRefGoogle Scholar
  20. 20.
    Xie H, Sun T, Chen M, et al., Effectiveness of the apparent diffusion coefficient for predicting the response to chemoradiation therapy in locally advanced rectal cancer, Medicine, 2015;94(6):e517.CrossRefGoogle Scholar
  21. 21.
    Song I, Kim SH, Lee SJ, et al., Value of diffusion-weighted imaging in the detection of viable tumour after neoadjuvant chemoradiation therapy in patients with locally advanced rectal cancer: comparison with T2 weighted and PET/CT imaging, Br J Radiol, 2012;85:577-586.CrossRefGoogle Scholar
  22. 22.
    Cai G, Xu Y, Zhu J, et al., Diffusion-weighted magnetic resonance imaging for predicting the response of rectal cancer to neoadjuvant concurrent chemoradiation, World J Gastroenterol, 2013;19(33):5520-5527.CrossRefGoogle Scholar
  23. 23.
    Moffat BA, Chenevert TL, Lawrence TS, et al., Functional diffusion map: a noninvasive MRI biomarker for early stratification of clinical brain tumor response, Proc Natl Acad Sci USA, 2005;102:5524-5529.CrossRefGoogle Scholar
  24. 24.
    Kim SH, Lee JY, Lee JM, Han JK, Choi BI, Apparent diffusion coefficient for evaluating tumour response to neoadjuvant chemoradiation therapy for locally advanced rectal cancer, Eur Radiol, 2011;21:987-995.CrossRefGoogle Scholar
  25. 25.
    Lee EM, Hong YS, Kim KP, et al., Phase II study of preoperative chemoradiation with S-1 plus oxaliplatin in patients with locally advanced rectal cancer, Cancer Sci, 2013;104:111-115.CrossRefGoogle Scholar
  26. 26.
    Curvo-Semedo L, Lambregts DMJ, Maas M, et al., Rectal Cancer: assessment of complete response to preoperative combined radiation therapy with chemotherapy - Conventional MR volumetry versus diffusion-weighted MR imaging, Radiology, 2011;260:734-743.CrossRefGoogle Scholar
  27. 27.
    Dzik-Jurasz A, Domenig C, George M, et al., Diffusion MRI for prediction of response of rectal cancer to chemoradiation, Lancet, 2002;360:307-308.CrossRefGoogle Scholar
  28. 28.
    Koh DM, Collins DJ, Diffusion-weighted MRI in the body: applications and challenges in oncology, Am J Roentgenol, 2007;188:1622-1635.CrossRefGoogle Scholar
  29. 29.
    Harrison L, Blackwell K, Hypoxia and anemia: factors in decreased sensitivity to radiation therapy and chemotherapy?, Oncologist, 2004;9:31-40.CrossRefGoogle Scholar
  30. 30.
    Jung SH, Heo SH, Kim JW, et al., Predicting response to neoadjuvant chemoradiation therapy in locally advanced rectal cancer: diffusion-weighted 3 Tesla MR imaging, J Magn Reson Imaging, 2012;35:110-116.CrossRefGoogle Scholar
  31. 31.
    Petrelli F, Sgroi G, Sarti E, Barni S, Increasing the interval between neoadjuvant chemoradiotherapy and surgery in rectal cancer: a meta-analysis of published studies, Ann Surg, 2016;263:458-464.CrossRefGoogle Scholar
  32. 32.
    Probst CT, Becerra AZ, Aquina CT, et al., Extended intervals after neoadjuvant therapy in locally advanced rectal cancer: the key to improved tumor response and potential organ preservation, J Am Coll Surg, 2015;221(2):430-440.CrossRefGoogle Scholar
  33. 33.
    Sloothaak DA, Geijsen DE, van Leersum NJ, et al., Optimal time interval between neoadjuvant chemoradiotherapy and surgery for rectal cancer, Br J Surg, 2013;100:933-939.CrossRefGoogle Scholar
  34. 34.
    Joye I, Debucquoy A, Deroose C, et al., Quantitative imaging outperforms molecular markers when predicting response to chemoradiotherapy for rectal cancer, Radiother Oncol, 2017;124(1):104-109.CrossRefGoogle Scholar
  35. 35.
    Eisenhauer EA, Therasse P, Bogaerts J, et al., New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1), Eur J Cancer, 2009;45:228-247.Google Scholar
  36. 36.
    Xiao J, Tan Y, Li W, et al., Tumor volume reduction rate is superior to RECIST for predicting the pathological response of rectal cancer treated with neoadjuvant chemoradiation: results from a prospective study, Oncol Lett, 2015;9(6):2680-2686.CrossRefGoogle Scholar
  37. 37.
    Kim YC, Lim JS, Keum KC, et al., Comparison of diffusion-weighted MRI and MR volumetry in the evaluation of early treatment outcomes after preoperative chemoradiotherapy for locally advanced rectal cancer, J Magn Reson Imaging, 2011; 34(3):570-576.CrossRefGoogle Scholar
  38. 38.
    Ha HI, Kim AY, Yu CS, Park SH, Ha HK, Locally advanced rectal cancer: diffusion-weighted MR tumour volumetry and the apparent diffusion coefficient for evaluating complete remission after preoperative chemoradiation therapy, Eur Radiol, 2013;23(12):3345-3353.CrossRefGoogle Scholar
  39. 39.
    Nougaret S, Vargas HA, Lakhman Y, et al., Intravoxel Incoherent Motion histogram metrics for assessment of response after combined chemotherapy and radiation therapy in rectal cancer: initial experience and comparison between single-section and volumetric analyses, Radiology, 2016;280(2):446-454.CrossRefGoogle Scholar
  40. 40.
    Kim SH, Lee JM, Gupta SN, Han JK, Choi BI, Dynamic contrast enhancement MRI to evaluate the therapaeutic response to neoadjuvant chemoradiation therapy in locally advanced rectal cancer, J Magn Reson Imaging, 2014;40(3):730-737.CrossRefGoogle Scholar
  41. 41.
    Intven M, Monninkhof EM, Reerink O, Philippens ME, Combined T2w volumetry, DW-MRI and DCE-MRI for response assessment after neo-adjuvant chemoradiation in locally advanced rectal cancer, Acta Oncol, 2015;27:1-8.Google Scholar
  42. 42.
    Nie K, Shi L, Chen Q, et al., Rectal cancer: assessment of neoadjuvant chemo-radiation outcome based on radiomics of multi-parametric MRI, Clin Cancer Res, 2016;22(21):5256-5264.CrossRefGoogle Scholar
  43. 43.
    Lambregts DMJ, Maas M, Riedl RG, et al., Value of ADC measurement for nodal staging after chemoradiation in locally advanced rectal cancer - a per lesion validation study, Eur Radiol, 2010;21:265-273.CrossRefGoogle Scholar
  44. 44.
    van Heeswijk MM, Lambregts DMJ, Palm WM, et al., DWI for assessment of rectal cancer nodes after chemoradiotherapy: is the absence of nodes at DWI proof of a negative nodal status?, Am J Roentgenol, 2017;208(3):w79-w84.CrossRefGoogle Scholar
  45. 45.
    Lahaye MJ, Engelen SM, Kessels AG, et al., USPIO-enhanced MR imaging for nodal staging in patients with primary rectal cancer: predictive criteria, Radiology, 2008;246:804-811.CrossRefGoogle Scholar
  46. 46.
    Heijnen LA, Lambregts DMJ, Martens MH, et al., Performance of gadofosveset-enhanced MRI for staging rectal cancer nodes: can the initial promising results be reproduced?, Eur Radiol, 2014;24:371-379.CrossRefGoogle Scholar
  47. 47.
    Blazic IM, Lilic GB, Gajic MM, Quantitative assessment of rectal cancer response to neoadjuvant combined chemotherapy and radiation therapy: comparison of three methods of positioning region of interest for ADC measurements at diffusion-weighted MR imaging, Radiology, 2017;282(2):418-428.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Division of Radiology 2, Department of Surgical and Biomedical SciencesSanta Maria della Misericordia HospitalPerugiaItaly
  2. 2.Section of Anatomic Pathology and Histology, Department of Experimental MedicineSanta Maria della Misericordia HospitalPerugiaItaly
  3. 3.Division of Gynaecology, Department of Surgical and Biomedical SciencesSanta Maria della Misericordia HospitalPerugiaItaly
  4. 4.Section of Radiation Oncology, Department of Surgical and Biomedical SciencesSanta Maria della Misericordia HospitalPerugiaItaly

Personalised recommendations